{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:24:01Z","timestamp":1791379441057,"version":"4.3.2"},"reference-count":76,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose of Review\nThis is a comprehensive review of the literature regarding the use of Lofexidine for opiate withdrawal symptoms. It covers the background and necessity of withdrawal programs and the management of withdrawal symptoms and then covers the existing evidence of the use of Lofexidine for this purpose.\nRecent Findings\nOpiate abuse leads to significant pain and suffering. However, withdrawal is difficult and often accompanied by withdrawal symptoms and renewed cravings. These symptoms are driven mostly by signaling in the locus coeruleus and the mesolimbic system and a rebound increase in noradrenaline, producing symptoms such as anxiety, gastrointestinal upset, and tension. Lofexidine, an alpha-2 agonist, can be used to manage acute withdrawal symptoms before starting maintenance treatment with either methadone or buprenorphine. Lofexidine, if FDA approved for management of withdrawal symptoms and has been proved to be both effective and safe.\nSummary\nOpiate addiction is increasing and plaguing the western world and specifically the U.S. It takes a large toll on both a personal and societal level and carries a high cost. Withdrawal is difficult, both related to withdrawal symptoms and renewed cravings. Lofexidine has been shown to be effective in reducing the former and could potentially aid in recovery and withdrawal.<\/jats:p>","DOI":"10.64719\/pb.4615","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"76-96","source":"Crossref","is-referenced-by-count":9,"title":["A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms"],"prefix":"10.64719","volume":"50","author":[{"given":"Ivan","family":"Urits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie","family":"Zusman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina Guadalupe","family":"Virgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Dydyk AM1, Jain NK2 GM. Opioid Use Disorder. 2020 StatPearls."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Stoicea N, Costa A, Periel L, Uribe A, Weaver T, Bergese SD. Current perspectives on the opioid crisis in the U.S. healthcare system. Medicine (Baltimore) 2019;98(20):e15425.","DOI":"10.1097\/MD.0000000000015425"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Pergolizzi JV, Varrassi G, Paladini A, LeQuang J. Stopping or Decreasing Opioid Therapy in Patients on Chronic Opioid Therapy. Pain Ther. 2019;8(2):163\u2013176.","DOI":"10.1007\/s40122-019-00135-6"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol Annu Rev Pharmacol Toxicol. 2018;58:143\u2013159.","DOI":"10.1146\/annurev-pharmtox-010617-052534"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Olfson M, Rossen LM, Wall MM, Houry D, Blanco C. Trends in Intentional and Unintentional Opioid Overdose Deaths in the United States, 2000\u20132017. Vol. 322, JAMA\u2014Journal of the American Medical Association. American Medical Association. 2019:2340\u20132342.","DOI":"10.1001\/jama.2019.16566"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Rose ME. Are prescription opioids driving the opioid crisis? assumptions vs facts. 2018 Pain Med (United States)","DOI":"10.1093\/pm\/pnx048"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Soelberg CD, Brown RE, Du Vivier D, Meyer JE, Ramachandran BK. The U.S. Opioid Crisis: Current Federal and State Legal Issues. Anesth Analg. 2017;125(5):1675\u20131681.","DOI":"10.1213\/ANE.0000000000002403"},{"key":"ref8","unstructured":"Ahmad FB, Rossen LM, SUtton P. Provisional drug overdose death counts. National Center for Health Statistics. 2020"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet (London, England) 2019;393(10182):1760\u20131772.","DOI":"10.1016\/S0140-6736(18)33078-2"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Chiu AW, Contreras S, Mehta S, Korman J, Perreault MM, Williamson DR et al. Iatrogenic Opioid Withdrawal in Critically Ill Patients: A Review of Assessment Tools and Management. Annals of Pharmacotherapy. 2017","DOI":"10.1177\/1060028017724538"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Pergolizzi JV, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther. 2020 Jan","DOI":"10.1111\/jcpt.13114"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Suffoletto B, Zeigler A. Risk and protective factors for repeated overdose after opioid overdose survival. Drug Alcohol Depend. 2020;209:107890.","DOI":"10.1016\/j.drugalcdep.2020.107890"},{"key":"ref13","unstructured":"WHO. Withdrawal Management. In: Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Setting 2009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Choi B. Opioid use disorder, job strain, and high physical job demands in U.S. workers. Int Arch Occup Environ Health. 2020","DOI":"10.1007\/s00420-019-01514-4"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Uniyal A, Gadepalli A, Akhilesh, Tiwari V. Underpinning the Neurobiological Intricacies Associated with Opioid Tolerance. ACS Chem Neurosci. 2020;11(6):830\u2013839.","DOI":"10.1021\/acschemneuro.0c00019"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Burma NE, Kwok CH, Trang T. Therapies and mechanisms of opioid withdrawal. Pain Manag. 2017;7(6):455\u2013459.","DOI":"10.2217\/pmt-2017-0028"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pergolizzi JV, Rosenblatt M, Mariano DJ, LeQuang JA. Clinical considerations about opioid withdrawal syndrome. Pain Manag. 2019;9(2):111\u2013113.","DOI":"10.2217\/pmt-2018-0088"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Nonopioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. J Pharmacol Exp Ther. 2019;371(2):422\u2013452.","DOI":"10.1124\/jpet.119.258004"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Ellis MS. Understanding the demand side of the prescription opioid epidemic: Does the initial source of opioids matter? Drug Alcohol Depend. 2017;173:S4\u2013S10.","DOI":"10.1016\/j.drugalcdep.2016.03.014"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Frank JW, Levy C, Matlock DD, Calcaterra SL, Mueller SR, Koester S et al. Patients\u2019 Perspectives on Tapering of Chronic Opioid Therapy: A Qualitative Study. Pain Med. 2016;17(10):1838\u20131847.","DOI":"10.1093\/pm\/pnw078"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Weiss RD, Potter JS, Griffin ML, McHugh RK, Haller D, Jacobs P et al. Reasons for opioid use among patients with dependence on prescription opioids: The role of chronic pain. J Subst Abuse Treat. 2014;47(2):140\u2013145.","DOI":"10.1016\/j.jsat.2014.03.004"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. Lippincott Williams and Wilkins. 2015;9:358\u2013367. Vol. Journal of Addiction Medicine.","DOI":"10.1097\/ADM.0000000000000166"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ayanga D, Shorter D, Kosten TR. Update on pharmacotherapy for treatment of opioid use disorder. 2016;17:2307\u20132318. Vol. Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd.","DOI":"10.1080\/14656566.2016.1244529"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55\u201362.","DOI":"10.1111\/ajad.12862"},{"key":"ref25","unstructured":"Food and Drug Administration. Subutex (buprenorphine sublingual tablets)\u2014FDA 2018"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gowing L, Farrell M, Ali R, White JM. Vol. 2016. John Wiley and Sons Ltd; 2016. Alpha2-adrenergic agonists for the management of opioid withdrawal. Vol. Cochrane Database of Systematic Reviews.","DOI":"10.1002\/14651858.CD002024.pub5"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Carnwath T, Hardman JA. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50(3):251\u2013254.","DOI":"10.1016\/S0376-8716(98)00040-4"},{"key":"ref28","unstructured":"Food and Drug Administration 2018 LUCEMYRATM (lofexidine) tablets labeling."},{"key":"ref29","unstructured":"Choy M. Pharmaceutical Approval Update. Pharm Ther. 2018;43(8):461\u2013462."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, et al. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend. 2008;97(1\u20132):158\u2013168.","DOI":"10.1016\/j.drugalcdep.2008.04.002"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 1988;21(3):253\u2013259.","DOI":"10.1016\/0376-8716(88)90078-6"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Gillis R, Gatti P, Quest JA. Mechanism of the antihypertensive effect of alpha 2-agonists. J Cardiovasc Pharmacol. 1985;7(Suppl 8)","DOI":"10.1097\/00005344-198500078-00007"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Buerkle H, Yaksh TL. Pharmacological evidence for different alpha2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth. 1998;81(2):208\u2013215.","DOI":"10.1093\/bja\/81.2.208"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth Prog. 2015 Mar;62(1):31\u201338.","DOI":"10.2344\/0003-3006-62.1.31"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: From second- to first-line sedative agents in the critical care setting? Journal of Intensive Care Medicine. 2012;27:219\u2013237. Vol.","DOI":"10.1177\/0885066610396815"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Al-Ghananeem AM. Pharmacokinetics, pharmacodynamics and drug metabolism: Pharmaeokineties of lofexidine hydrochloride in healthy volunteers. J Pharm Sci. 2009;98(1):319\u2013326.","DOI":"10.1002\/jps.21401"},{"key":"ref37","unstructured":"Lofexidine C11H12Cl2N2O\u2014PubChem."},{"key":"ref38","unstructured":"Lofexidine Hydrochloride Briefing Document Psychopharmacol Drugs Advis Comm. 2018"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Lopez LM, Mehta JL. Long-term experience with lofexidine in the treatment of mild-to-moderate essential hypertension. Drug Intell Clin Pharm. 1985;19(12):928\u2013932.","DOI":"10.1177\/106002808501901214"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Vlachakis ND, Velasquez M, Alexander N, Maronde RF. Hemodynamic effect of lofexidine with a diuretic in hypertension. Clin Pharmacol Ther. 1983;34(6):764\u2013769.","DOI":"10.1038\/clpt.1983.247"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Lopez LM, Mehta JL. Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension. Am J Cardiol. 1984","DOI":"10.1016\/0002-9149(84)90405-3"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Wilkins LH, Winternitz SR, Oparil S, Smith LR, Dustan HP. Lofexidine and clonidine in moderate essential hypertension. Clin Pharmacol Ther. 1981;30(6):752\u2013757.","DOI":"10.1038\/clpt.1981.234"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Schultz HS, Chretien SD, Brewer DD, Eltorai MI, Weber MA. Centrally Acting Antihypertensive Agents: A Comparison of Lofexidine with Clonidine. J Clin Pharmacol. 1981","DOI":"10.1002\/j.1552-4604.1981.tb01751.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Fouad FM, Vidt DG, Williams H, Tarazi RC, Bravo EL. Early hemodynamic and humoral effects of lofexidine. Clin Pharmacol Ther. 1981;29(4):498\u2013504.","DOI":"10.1038\/clpt.1981.69"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Fagan T, Bloomfield S, Cowart T, Corns-Hurwitz R, Lipicky R, Conradi E, et al. Antihypertensive effects of lofexidine in patients with essential hypertension. Br J Clin Pharmacol. 1982;13(3):405\u2013410.","DOI":"10.1111\/j.1365-2125.1982.tb01393.x"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Garrett BN, Kaplan NM. Lofexidine in the Treatment of Hypertension: A Twice-Daily versus Once-Daily Dose Comparison with 24-Hour Blood Pressure Monitoring. J Clin Pharmacol. 1981;21(4):173\u201380.","DOI":"10.1002\/j.1552-4604.1981.tb05697.x"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Rehman SU, Maqsood MH, Bajwa H, Tameez Ud Din A, Malik MN. Clinical Efficacy and Safety Profile of Lofexidine Hydrochloride in Treating Opioid Withdrawal Symptoms: A Review of Literature. Cureus. 2019;11(6):4\u201311.","DOI":"10.7759\/cureus.4827"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. J Addict Med. 2019;13(3):169\u2013176.","DOI":"10.1097\/ADM.0000000000000474"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Darp\u00f6 B, Pirner M, Longstreth J, Ferber G. Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal. Drug Alcohol Depend. 2019;205","DOI":"10.1016\/j.drugalcdep.2019.107596"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Gorodetzky CW, Walsh SL, Martin PR, Saxon AJ, Gullo KL, Biswas K. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend. 2017;176(4):79\u201388.","DOI":"10.1016\/j.drugalcdep.2017.02.020"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95(7):915\u2013918.","DOI":"10.1016\/j.amjcard.2004.11.055"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Schmittner J, Schroeder JR, Epstein DH, Krantz MJ, Eid NC, Preston KL. Electrocardiographic effects of lofexidine and methadone coadministration: Secondary findings from a safety study. Pharmacotherapy. 2009;29(5):495\u2013502.","DOI":"10.1592\/phco.29.5.495"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Schroeder JR, Schmittner J, Bleiberg J, Epstein DH, Krantz MJ, Preston KL. Hemodynamic and cognitive effects of lofexidine and methadone coadministration: A pilot study. Pharmacotherapy. 2007;27(8):1111\u20131119.","DOI":"10.1592\/phco.27.8.1111"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Kuszmaul AK, Palmer EC, Frederick EK. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review. J Am Pharm Assoc. 2020;60(1):145\u2013152.","DOI":"10.1016\/j.japh.2019.10.004"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S et al. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat. 2001;21(1):11\u201317.","DOI":"10.1016\/S0740-5472(01)00178-7"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44(1):57\u201361.","DOI":"10.1016\/S0376-8716(96)01316-6"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48(2):127\u2013133.","DOI":"10.1016\/S0376-8716(97)00116-6"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12(5):448\u2013453.","DOI":"10.1007\/s11920-010-0135-5"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Hermes G, Hyman SM, Fogelman N, Kosten TR, Sinha R. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. Am J Addict. 2019;28(6):480\u2013488.","DOI":"10.1111\/ajad.12942"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Sinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: Preliminary findings. Psychopharmacology (Berl) 2007;190(4):569\u2013574.","DOI":"10.1007\/s00213-006-0640-8"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Bearn J, Bennett J, Martin T, Gossop M, Strang J. The impact of naloxone\/lofexidine combination treatment on the opiate withdrawal syndrome. Addict Biol. 2001;6(2):147\u2013156.","DOI":"10.1080\/13556210020040226"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Guo S, Manning V, Yang Y, Koh PK, Chan E, de Souza NN et al. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. J Subst Abuse Treat. 2018;91(4):1\u201311.","DOI":"10.1016\/j.jsat.2018.04.012"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Law FD, Diaper AM, Melichar JK, Coulton S, Nutt DJ, Myles JS. Buprenorphine\/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals. J Psychopharmacol. 2017;31(8):1046\u20131055.","DOI":"10.1177\/0269881117711710"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Gossop M, Bradley B. Measures of sleep disturbance were taken among drug-dependent inpatients being withdrawn from opiates using either a conventional oral methadone regime or electrostimulation (E.S.). Sleep was found to be disturbed in both groups. Subjects receiving E.S. sh. Drug Alcohol Depend. 1984;13","DOI":"10.1016\/0376-8716(84)90058-9"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Beswick T, Best D, Rees S, Bearn J, Gossop M, Strang J. Major disruptions of sleep during treatment of the opiate withdrawal syndrome: Differences between methadone and lofexidine detoxification treatments. Addict Biol. 2003;8(1):49\u201357.","DOI":"10.1080\/1355621031000069882"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Juurlink DN. Lofexidine for Opioid Withdrawal: Small Effects at an Exorbitant Price. J Addict Med. 2019;13(3):167\u2013168.","DOI":"10.1097\/ADM.0000000000000473"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Alam D, Tirado C, Pirner M, Clinch T. Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials. J Drug Assess. 2020;9(1):13\u201319.","DOI":"10.1080\/21556660.2019.1704416"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Meader N. A comparison of methadone, buprenorphine and alpha2 adrenergic agonists for opioid detoxification: A mixed treatment comparison meta-analysis. Drug Alcohol Depend. 2010;108(1\u20132):110\u2013114.","DOI":"10.1016\/j.drugalcdep.2009.12.008"},{"key":"ref69","unstructured":"Rapid Drug Detoxification. Kaye AD, Gevirtz C, Bosscher HA, Duke JB, Richards TA, Fields AM, Frost AE. Eur J Allied Health. 2001;2(3):56\u201361."},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"A Complete Review of Ultra Rapid Opiate Detoxification. Kaye AD, Gevirtz C, Bosscher HA, Duke JB, Richards TA, Fields AM, Frost AE. Can J Anaesth. 2003;50(7):663\u2013671.","DOI":"10.1007\/BF03018708"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Ultrarapid Opiate Detoxification a Review. Kaye AD, Gevirtz C, Bosscher HA, Hegazi A, Sabar R, Duke JB, Richards TA, Fields AM, Frost EA. Can J Anesth. 2003;50(7):663\u2013671.","DOI":"10.1007\/BF03018708"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Chronic Pain and Ultrarapid Opioid Detoxification. Kaye AD, Banister RE, Hoover JM, Baluch AR, Jacobs S, Shah R. Pain Practice. 2005;5(1):33\u201342.","DOI":"10.1111\/j.1533-2500.2005.05105.x"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Gevirtz CM, Frost E, Kaye AD. Opiate Detoxification (Ultra Rapid Detoxification), an Update, in Anesthesia Outside of the Operating Room. In: Urman RD, Gross WL, Philip BL, editors; 2011 edition. Oxford Press; pp. 309\u2013315. chapter 32.","DOI":"10.1093\/med\/9780195396676.003.0032"},{"key":"ref74","unstructured":"Anesthesia Assisted Rapid Opiate Detoxification. Gevirtz C, Kaye AD. 2014:447\u2013455. Clinical Cases in Pain Management, editors Kaye AD, Shah R, Cambridge Press. chapter 64."},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Detoxification Techniques for Opiates and Benzodiazepines. Gevirtz C, Kaye AD. 2016:49\u201356. Pain Management and Palliative Care, editor Sackheim K, Springer Press, Chapter 8.","DOI":"10.1007\/978-1-4939-2462-2_8"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Gevirtz CM, Frost E, Kaye AD. Opiate Detoxification (Ultra Rapid Detoxification), an Update, in Anesthesia Outside of the Operating Room. In: Urman RD, Gross WL, Philip BL, editors; 2018 edition. Oxford Press; chapter 32.","DOI":"10.1093\/med\/9780190495756.003.0035"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:35:54Z","timestamp":1791315354000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/a-comprehensive-update-of-lofexidine-for-the-management-of-opioid-withdrawal-symptoms\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4615","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}